Early response to chemotherapy in hypopharyngeal cancer: Assessment with 11c-methionine PET, correlation with morphologic response, and clinical outcome

Journal of Nuclear Medicine

Volumn 44, Issue 4, 2003, Pages 526-532

  Chesnay, Eric ^a   Babin, Emmanuel ^a   Constans, Jean Marc ^a   Agostini, Denis ^a   Bequignon, Arnaud ^a   Regeasse, Armelle ^a   Sobrio, Franck ^b   Moreau, Sylvain ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b GIP CYCERON   (France)

Author keywords

11C methionine; Chemotherapy monitoring; Hypopharyngeal cancer; PET

Indexed keywords

CISPLATIN; FLUOROURACIL; METHIONINE C 11; ANTINEOPLASTIC AGENT; CARBON 11 METHIONINE; CARBON-11 METHIONINE; DIAGNOSTIC AGENT; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; HUMAN; HYPOPHARYNX CARCINOMA; INTERMETHOD COMPARISON; MEASUREMENT; METABOLISM; METHODOLOGY; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR; TUMOR VOLUME; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HYPOPHARYNX TUMOR; MALE; MIDDLE AGED; SCINTISCANNING; STATISTICS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0037639972     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949-955.
2. Cognetti F, Pinnaro P, Ruggeri EM, et al. Prognostic factors for chemotherapy responses and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 1989;7:829-837.
3. Schelling M, Avril N, Nahrig J, et al Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695
4. 18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastalic breast cancer patients. Clin Breast Cancer. 2000; 1:156-161.
5. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease J Nucl Med. 2002;43:1018-1027.
6. Bokemeyer C, Kollmannsberger C, Oechsle K, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer. 2002;86:506-511.
7. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
8. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
9. Erdi YE, Macapinlac H, Rosenzweig KE, et al Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-866.
10. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613-618.
11. 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med. 2000;41:999-1005.
12. Kitagawa Y, Sadato N, Azuma H, et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 1999;40:1132-1137.
13. Sakamoto H, Nakai Y, Ohashi Y, et al Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas. Acta Otolaryngol Suppl. 1998;538:254-260.
14. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer Br J Surg 1998;85:1403-1406.
15. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with HDG PET. J Nucl Med 1999; 40:1424-1433.
16. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med. 1992;33:691-695
17. Lindholm P, Leskinen-Kallio S, Minn H, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer J Nucl Med. 1993;34:1711-1716.
18. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000;48:43-52.
19. 11C]methionine. Int J Radiat Oncol Biol Phys 1995;32:787-794.
20. Hermanek P, Sobin LH, eds. UICC TNM Classification of Malignant Tumors. 4th ed., 2nd revision Berlin, Germany: Springer-Verlag; 1992.
21. Lowe VJ, Duhaylongsod FG, Patz EF, et al Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology. 1997;202:435-439.
22. 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med. 2000;41:283-290.
23. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
24. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations Eur J Cancer. 1999;35:1773-1782
25. Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36: 1836-1839.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
27. Parkin DM, Murr CS, Whelan SL, et al. Cancer incidence in five continents. IARC Sci Publ. 1992;120:45-173
28. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck cancer: PET imaging with 2-(F-18)fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology. 1993;186:27-35.
29. Anzai Y, Caroll WR, Quint DJ, et al Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-(F-18)fluoro- D-glucose PET and MR imaging diagnoses. Radiology. 1996;200:135-141.
30. Greven K, Williams D, Keyes J, et al Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355-1359.
31. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378.
32. Lindholm P, Leskinen S, Lapela M. Carbon-11-methionine uptake in squamous cell head and neck cancer. J Nucl Med. 1998;39:1393-1397.
33. 11C]methionine-positron emission tomography. Radiother Oncol. 1999;52:225-232.
34. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13: 1470-1477.
35. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer. 1993;67:787-791.
36. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography Clin Cancer Res. 2001;7:2269-2276.
37. 11C]niethionine, [6-3H]thymidine, and gallium-67 J Nucl Med. 1991;32:2118-2123.
38. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck J Nucl Med. 1995;36:252-258.
39. 11CImethionine. J Nucl Med. 1987;28:1037-1040.
40. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.